Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in
chemonaive patients with locally advanced or metastatic non–small cell lung cancer …

Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …

BACKGROUND The primary objectives of this study were to determine the efficacy and
tolerability of a pemetrexed‐carboplatin combination as first‐line therapy in patients with …

Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in
pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and …

Purpose To compare single-agent pemetrexed (P) versus the combination of carboplatin
and pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung …

Purpose To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients
with advanced non—small-cell lung cancer (NSCLC) previously treated with chemotherapy …

Background To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-
naïve patients with surgically incurable non-small-cell lung cancer (NSCLC). Patients and …

Purpose We performed a randomized phase II trial comparing pemetrexed with pemetrexed
plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy …

Objective Pemetrexed has been approved for second-line treatment in non-small cell lung
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …